Teva Pharmaceutical Industries Investor Presentation — July 2022

Document content

Teva Pharmaceutical Industries Ltd.

Second Quarter 2022 Results

Opioid litigation updates

Second quarter 2022 results

Strategy update and 2027 long-term financial targets

AgendaThis presentation contains forward-looki ng statements within the meaning of the Private Securities Litigation Reform Act of 199 5, which are based on management’s current beliefs and expectations and are subject

to substantial risks and uncertainties, both known and unknown, that could cause our future resu lts, performance or achievement s to differ significantly from that expre ssed or implied by such forward-looking

statements. Important factors that could cause or contribute to such differences include risks relating to:

• our ability to successfully compete in the marketplace, in cluding: that we are substant ially dependent on our generic products ; consolidation of our customer base and commercial alliances among our customers;

delays in launches of new generic products; the increase in the number of competitor s targeting generic opportunities and seeki ng U.S. market exclusivity for generic versi ons of significant products; our ability to

develop and commercialize biopharmaceutical products; compet ition for our specialty products, including AUSTEDO®, AJOVY®and COPAXONE®; our ability to achieve expected re sults from investments in our

product pipeline; our ability to develop and commercialize additi onal pharmaceutical products; and the effectiveness of our pa tents and other measures to protec t our intellectual property rights;

• our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions o r make new investments, may result in a further downgrade of our credit ratings; and

our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;

• our business and operations in general, including: uncertainty regarding the COVID-19 pandemic and the governmental and societ al responses thereto; our ability to successfully execute and maintain the

activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated co sts therewith; effectiveness of our optimization efforts; our ability to attract, hire

and retain highly skilled personnel; manufacturing or quality control problems; interruptions in our supply chain; disruptions of information technology systems; breaches of our data security; variations in

intellectual property laws; challenges associated with conducti ng business globally, including political or economic instabilit y, major hostilities or terrorism; costs and delays resulting from the extensive